Recently, other newly developed anti-TIGIT mAbs including four humanized IgG1 mAb targeted TIGIT (domvanalimab, ociperlimab, rilvegotomig, and tiragolumab) are under evaluation in several phase I/II studies for NSCLC patients (Table 4). Here, TIGIT is linked to non-small cell lung carcinoma.